OPKO Health Stock Earnings Estimates Lifted by HC Wainwright

OPKO Health, Inc. (NASDAQ:OPK) – Research analysts at HC Wainwright raised their FY2026 earnings per share estimates for OPKO Health in a research report issued on Thursday, November 5th. HC Wainwright analyst Y. Chen now anticipates that the biotechnology company will post earnings of ($0.18) per share for the year, up from their previous estimate of ($0.23). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for OPKO Health’s current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for OPKO Health’s Q4 2026 earnings at ($0.11) EPS, Q1 2027 earnings at ($0.10) EPS, Q3 2027 earnings at ($0.05) EPS, Q4 2027 earnings at ($0.05) EPS and FY2027 earnings at ($0.27) EPS.

Several other equities analysts have also recently issued reports on the stock. Piper Sandler restated an “overweight” rating and issued a $4.00 price target (up from $3.00) on shares of OPKO Health in a research report on Friday, October 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of OPKO Health in a report on Thursday, August 13th. Zacks Research cut shares of OPKO Health from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 6th. UBS Group set a $4.00 price objective on shares of OPKO Health in a research note on Friday, October 16th. Finally, Barrington Research upgraded OPKO Health from a “market perform” rating to an “outperform” rating and set a $2.25 price objective for the company in a report on Friday, October 16th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, OPKO Health currently has a consensus rating of “Hold” and an average target price of $3.42.

OPKO Health Price Performance

NASDAQ:OPK opened at $1.71 on Monday. OPKO Health has a one year low of $0.98 and a one year high of $1.86. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.97 and a quick ratio of 4.65. The company has a market cap of $1.27 billion, a PE ratio of -9.00 and a beta of 1.52. The firm’s 50 day simple moving average is $1.60 and its 200 day simple moving average is $1.36.

OPKO Health (NASDAQ:OPK) last issued its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.07). OPKO Health had a negative net margin of 29.51% and a negative return on equity of 10.90%. The business had revenue of $130.83 million during the quarter, compared to analyst estimates of $136.62 million. During the same quarter last year, the business earned $0.03 EPS. The firm’s quarterly revenue was down 56.9% on a year-over-year basis.

Institutional Trading of OPKO Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Voya Investment Management LLC increased its position in shares of OPKO Health by 9.6% during the third quarter. Voya Investment Management LLC now owns 1,198,779 shares of the biotechnology company’s stock worth $1,930,000 after buying an additional 104,668 shares during the period. Fifth Third Bancorp grew its holdings in OPKO Health by 8.8% during the 3rd quarter. Fifth Third Bancorp now owns 185,000 shares of the biotechnology company’s stock worth $298,000 after acquiring an additional 15,000 shares during the period. StoneX Group Inc. acquired a new stake in OPKO Health during the 3rd quarter worth about $47,000. State of Wyoming grew its holdings in OPKO Health by 154.6% during the 3rd quarter. State of Wyoming now owns 296,574 shares of the biotechnology company’s stock worth $477,000 after acquiring an additional 180,085 shares during the period. Finally, Partners Wealth Management LLC bought a new position in shares of OPKO Health in the 3rd quarter worth about $43,000. Institutional investors and hedge funds own 64.63% of the company’s stock.

About OPKO Health

OPKO Health is a healthcare company with businesses in diagnostics and pharmaceuticals. Its diagnostic offerings have included BioReference Health laboratory services and the 4Kscore test, which helps assess the risk of aggressive prostate cancer. OPKO’s pharmaceutical products include Rayaldee, a prescription treatment for certain adults with chronic kidney disease and vitamin D insufficiency. The company also co-developed NGENLA, a long-acting growth hormone treatment for children with growth hormone deficiency, with Pfizer.